The demo obtained the two its primary endpoints, with semaglutide two.four mg demonstrating statistically considerable and remarkable improvements in liver fibrosis without worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH compared to placebo.oneTell your health practitione